What Researchers Did
Researchers retrospectively investigated the efficacy of hyperbaric oxygen therapy (HBOT) in 75 patients with radiation-induced late side effects who completed a questionnaire documenting symptom severity.
What They Found
Improvement of principal presenting symptoms after HBOT was noted in 75% of head-and-neck, 100% of pelvic, and 57% of other subjects, with bone and bladder symptoms showing the highest response rates (81% and 83%, respectively). The median duration of response ranged from 62 to 72 weeks, while relapse incidence was low at 22%, and minor HBOT-related complications occurred in 31% of patients.
What This Means for Canadian Patients
Hyperbaric oxygen therapy may offer a safe and effective treatment option for Canadian patients experiencing specific radiation-induced late side effects, particularly those affecting bone and bladder. This therapy could provide durable relief for symptoms like osteoradionecrosis or soft tissue necrosis, especially when other interventions have failed.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
As a retrospective study with a 60% participation rate, the findings may be subject to selection bias and recall bias.